Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel therapies that harness the immune system to treat cancer. The company operates within the oncology and immuno-oncology segments of the biopharmaceutical industry, with a strategic emphasis on antibody-based therapies designed to improve outcomes for patients with solid tumors and hematologic malignancies.
The company’s primary product candidate is evorpacept (ALX148), an engineered fusion protein designed to block the CD47 immune checkpoint pathway while minimizing binding to red blood cells, a limitation observed in earlier CD47-targeting approaches. ALX Oncology was founded in 2015 and subsequently completed an initial public offering in 2020, transitioning from a privately funded biotechnology venture into a publicly traded clinical-stage company focused on advancing its lead asset through multiple clinical trials.
Business Operations
ALX Oncology operates as a single-reportable operating segment, concentrating its resources on research and development activities. The company does not generate product revenue and instead relies on equity financing, public offerings, and collaboration-related funding to support operations. Its business model centers on advancing evorpacept through Phase 1 and Phase 2 clinical studies, both as a monotherapy and in combination with other established cancer treatments such as chemotherapy, targeted agents, and immune checkpoint inhibitors.
Operations are primarily conducted in the United States, with clinical trials executed across multiple domestic and international sites. ALX Oncology maintains control over its proprietary CD47-blocking technology platform and associated intellectual property. The company has entered into clinical collaboration agreements with several large pharmaceutical companies to evaluate evorpacept in combination regimens; however, no material revenue-generating joint ventures or commercial partnerships have been disclosed as of the latest public filings.
Strategic Position & Investments
Strategically, ALX Oncology is focused on positioning evorpacept as a best-in-class CD47 pathway inhibitor by emphasizing its differentiated safety profile and combination potential. Growth initiatives center on expanding clinical indications, advancing later-stage trials, and generating data that could support regulatory approval. The company has invested heavily in clinical development programs targeting gastric, esophageal, head and neck, and other solid tumors, as well as select hematologic cancers.
ALX Oncology does not currently maintain a diversified portfolio of subsidiaries or marketed products. Its investment strategy is concentrated on internal research and development rather than acquisitions. Emerging areas of focus include combination immunotherapy strategies and potential expansion of its CD47 platform into additional oncologic indications, subject to clinical outcomes. Data inconclusive based on available public sources regarding any material acquisitions or equity investments in external portfolio companies.
Geographic Footprint
The company is headquartered in the United States, with its principal executive offices in California. ALX Oncology’s operational footprint is primarily domestic, centered on corporate management, research oversight, and clinical development activities. Clinical trials are conducted across North America, Europe, and parts of Asia, reflecting a geographically diverse patient enrollment strategy.
While ALX Oncology does not maintain large-scale international commercial operations, its global clinical trial presence provides it with international exposure and regulatory engagement across multiple jurisdictions. The company does not report foreign manufacturing facilities or permanent international offices beyond trial-related activities.
Leadership & Governance
ALX Oncology is led by an executive team with experience in oncology drug development, clinical research, and biopharmaceutical operations. The leadership emphasizes a strategy focused on scientific rigor, disciplined capital allocation, and advancing differentiated immuno-oncology therapies through data-driven clinical development.
Key executives include:
- Pankaj Mohan, M.D., Ph.D. – Chief Executive Officer
- Sophia Randolph – Chief Financial Officer
- Jaume Pons, Ph.D. – Chief Scientific Officer
- Thomas G. Hecht, M.D. – Chief Medical Officer
Information regarding the company’s original founders and detailed governance philosophy beyond publicly stated strategic priorities is limited; data inconclusive based on available public sources.